---
title: "Paxlovid (nirmatrelvir; ritonavir), all indications: Pharmacology questions"
description: "Pharmacology questions on Paxlovid (nirmatrelvir; ritonavir) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Paxlovid work (mechanism of action)? Why does Paxlovid contain ritonavir? Is Paxlovid active against Omicron and other variants in lab studies? Is there cross-resistance between Paxlovid and remdesivir? 3 further questions follow. 7 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/paxlovid/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Paxlovid (nirmatrelvir; ritonavir), all indications: Pharmacology questions

Manufacturer: Pfizer Inc  
Prescribing information: [Paxlovid](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599)  
Indication pages: [COVID-19](https://www.evicenter.com/medical-information/paxlovid--covid-19)

## Mechanism

<a id="paxlovid-mechanism"></a>

### How does Paxlovid work (mechanism of action)?

> “Nirmatrelvir is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drug [see Microbiology (12.4)].”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Nirmatrelvir%20is%20a%20severe%20acute,antiviral%20drug%20%5Bsee%20Microbiology%20%2812.4%29%5D.)

> “Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro), also referred to as 3C-like protease (3CLpro) or nonstructural protein 5 (nsp5) protease. Inhibition of SARS-CoV-2 Mpro renders it incapable of processing the viral polyproteins pp1a and pp1ab, preventing viral replication. Nirmatrelvir inhibited the activity of recombinant SARS-CoV-2 Mpro in a biochemical assay with a Ki value of 3.1 nM and an IC50 value of 19.2 nM. Nirmatrelvir was found to bind directly to the SARS-CoV-2 Mpro active site by X-ray crystallography.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Nirmatrelvir%20is%20a%20peptidomimetic%20inhibitor,active%20site%20by%20X%2Dray%20crystallography.)

> “Normal proteolysis
> M<sup>pro</sup> cuts the viral polyprotein chain to produce functional proteins, which enable viral replication
>
> Inhibition of proteolysis with PAXLOVID
> Nirmatrelvir binds to M<sup>pro</sup> so that functional viral proteins cannot be produced and viral replication is inhibited”

Source: [PAXLOVID: Mechanism of Action, captured 2026-11-13](https://paxlovid.pfizerpro.com/about-paxlovid/mechanism-of-action#:~:text=Normal%20proteolysis,and%20viral%20replication%20is%20inhibited)

<a id="paxlovid-why-ritonavir"></a>

### Why does Paxlovid contain ritonavir?

> “Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 Mpro. Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Ritonavir%20is%20an%20HIV%2D1%20protease%20inhibitor%20but,increased%20plasma%20concentrations%20of%20nirmatrelvir.)

> “Nirmatrelvir must be co-administered with ritonavir. Failure to correctly co-administer nirmatrelvir with ritonavir may result in plasma levels of nirmatrelvir that are insufficient to achieve the desired therapeutic effect.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Nirmatrelvir%20must%20be%20co%2Dadministered%20with%20ritonavir.%20Failure,achieve%20the%20desired%20therapeutic%20effect.)

<a id="paxlovid-variants"></a>

### Is Paxlovid active against Omicron and other variants in lab studies?

> “The antiviral activity of nirmatrelvir against the Omicron sub-variants BA.2, BA.2.12.1, BA.4, BA.4.6, BA.5, BF.7, BQ.1, BQ.1.11, XBB.1.5, EG.5, and JN.1 was assessed in Vero E6-TMPRSS2 cells in the presence of a P-gp inhibitor. Nirmatrelvir had a median EC50 value of 88 nM (range: 39-146 nM) against the Omicron sub-variants, reflecting EC50 value fold changes ≤1.8 relative to the USA-WA1/2020 isolate.
>
> In addition, the antiviral activity of nirmatrelvir against the SARS-CoV-2 Alpha, Beta, Gamma, Delta, Lambda, Mu, and Omicron BA.1 variants was assessed in Vero E6 P-gp knockout cells. Nirmatrelvir had a median EC50 value of 25 nM (range: 16-141 nM). The Beta variant was the least susceptible variant tested, with an EC50 value fold change of 3.7 relative to USA-WA1/2020. The other variants had EC50 value fold changes ≤1.1 relative to USA-WA1/2020.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=The%20antiviral%20activity%20of%20nirmatrelvir,changes%20%E2%89%A41.1%20relative%20to%20USA%2DWA1%2F2020.)

<a id="paxlovid-cross-resistance"></a>

### Is there cross-resistance between Paxlovid and remdesivir?

> “Cross-resistance is not expected between nirmatrelvir and remdesivir or any other anti-SARS-CoV-2 agents with different mechanisms of action (i.e., agents that are not Mpro inhibitors).”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Cross%2Dresistance%20is%20not%20expected%20between,that%20are%20not%20Mpro%20inhibitors%29.)

## Pharmacokinetics

<a id="paxlovid-metabolism"></a>

### How is Paxlovid metabolized and eliminated?

> “	Nirmatrelvir (When Given With Ritonavir)	Ritonavir”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Nirmatrelvir%20%28When%20Given%20With%20Ritonavir%29,Ritonavir)

> “Elimination
>
>
>
>
>   Major route of elimination
>
>
>
> Renal elimination
>
>
>
> Hepatic metabolism
>
>
>
>
>   Half-life (T½) (hr), mean
>
>
>
> 6.05*
>
>
>
> 6.15*
>
>
>
>
>   Oral clearance (CL/F) (L/hr), mean
>
>
>
> 8.99§
>
>
>
> 13.92§
>
>
>
>
> Metabolism
>
>
>
>
>   Metabolic pathways
>
>
>
> Nirmatrelvir is a CYP3A substrate but when dosed with ritonavir, metabolic clearance is minimal.
>
>
>
> Major CYP3A, Minor CYP2D6
>
>
>
>
> Excretion
>
>
>
>
>   % drug-related material in feces
>
>
>
> 35.3%¶
>
>
>
> 86.4%#
>
>
>
>
>   % of dose excreted as total (unchanged drug) in feces
>
>
>
> 27.5%¶
>
>
>
> 33.8%#
>
>
>
>
>   % drug-related material in urine
>
>
>
> 49.6%¶
>
>
>
> 11.3%#
>
>
>
>
>   % of dose excreted as total (unchanged drug) in urine
>
>
>
> 55.0%¶
>
>
>
> 3.5%#”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=112.4%C2%A7-,Elimination,3.5%25%23)

> “§
> 300 mg nirmatrelvir (oral suspension formulation) co-administered with 100 mg ritonavir (tablet formulation) twice daily for 3 days.
> ¶
> Determined by 19F-NMR analysis following 300 mg nirmatrelvir oral suspension administered at 0 hr enhanced with 100 mg ritonavir at -12 hours, 0 hours, 12 hours, and 24 hours.
> #
> Determined by 14C analysis following 600 mg 14C-ritonavir oral solution (6 times the approved ritonavir dose).”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=300%20mg%20nirmatrelvir%20%28oral%20suspension,times%20the%20approved%20ritonavir%20dose%29.)

Note: Table 3 columns are nirmatrelvir (given with ritonavir) followed by ritonavir.

<a id="paxlovid-half-life"></a>

### How long does Paxlovid stay in your system (half-life)?

> “	Nirmatrelvir (When Given With Ritonavir)	Ritonavir”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Nirmatrelvir%20%28When%20Given%20With%20Ritonavir%29,Ritonavir)

> “Half-life (T½) (hr), mean
>
>
>
> 6.05*
>
>
>
> 6.15*”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Half%2Dlife%20%28T%C2%BD%29%20%28hr%29%2C%20mean,6.15%2A)

> “*
> Represents data after a single dose of 300 mg nirmatrelvir (2 × 150 mg tablet formulation) administered together with 100 mg ritonavir tablet in healthy subjects.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Represents%20data%20after%20a%20single,ritonavir%20tablet%20in%20healthy%20subjects.)

> “Nirmatrelvir steady state was achieved on Day 2 following administration of the approved recommended dosage and the mean accumulation ratio was approximately 2-fold.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Nirmatrelvir%20steady%20state%20was%20achieved,accumulation%20ratio%20was%20approximately%202%2Dfold.)

Note: Table 3 columns are nirmatrelvir (given with ritonavir) followed by ritonavir.

## Components

<a id="paxlovid-inactive-ingredients"></a>

### What are the inactive ingredients in Paxlovid?

> “Nirmatrelvir is available as immediate-release, film-coated tablets. Each tablet contains 150 mg nirmatrelvir with the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and sodium stearyl fumarate. The following are the ingredients in the film coating: hydroxy propyl methylcellulose, iron oxide red, polyethylene glycol, and titanium dioxide.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Nirmatrelvir%20is%20available%20as%20immediate%2Drelease%2C,polyethylene%20glycol%2C%20and%20titanium%20dioxide.)

> “Ritonavir is available as film-coated tablets. Each tablet contains 100 mg ritonavir with the following inactive ingredients: anhydrous dibasic calcium phosphate, colloidal silicon dioxide, copovidone, sodium stearyl fumarate, and sorbitan monolaurate. The film coating may include the following ingredients: colloidal anhydrous silica, colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, polyethylene glycol, polysorbate 80, talc, and titanium dioxide.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Ritonavir%20is%20available%20as%20film%2Dcoated,80%2C%20talc%2C%20and%20titanium%20dioxide.)

## Related pages
- [Medical information: Paxlovid (nirmatrelvir; ritonavir): All indications](https://www.evicenter.com/medical-information/paxlovid)
- [Indication](https://www.evicenter.com/medical-information/paxlovid/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/paxlovid/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/paxlovid/safety)
- [Specific populations](https://www.evicenter.com/medical-information/paxlovid/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/paxlovid/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/paxlovid/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/paxlovid/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/paxlovid/access-and-coverage)
